Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

38.27
-0.8400-2.15%
Post-market: 38.290.0161+0.04%19:59 EDT
Volume:1.32M
Turnover:50.70M
Market Cap:3.28B
PE:-8.81
High:39.05
Open:38.73
Low:37.93
Close:39.11
Loading ...

US Health Secretary Reportedly Says 35 States to Join Pilot Program for Sickle Cell Disease Gene Therapies

MT Newswires Live
·
19 hours ago

CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards?

Zacks
·
Yesterday

CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know

Zacks
·
24 Apr

Crispr Therapeutics AG: Promising Growth with Casgevy Launch and Innovative Pipeline

TIPRANKS
·
22 Apr

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

Zacks
·
21 Apr

5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years

Motley Fool
·
20 Apr

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

Zacks
·
18 Apr

BofA Adjusts Price Target on CRISPR Therapeutics to $80 From $86, Keeps Buy Rating

MT Newswires Live
·
17 Apr

Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities

TIPRANKS
·
17 Apr

CRISPR Therapeutics (NasdaqGM:CRSP) Sees 25% Price Increase Over Last Week

Simply Wall St.
·
17 Apr

3 Magnificent Stocks That Could Double or More by 2030

Motley Fool
·
13 Apr

AI Biotech Stocks Shined. Recursion Soared 20% And Absci Surged 13%

Tiger Newspress
·
11 Apr

CRISPR Therapeutics AG (CRSP) Stock Moves -1.81%: What You Should Know

Zacks
·
11 Apr

Palantir, Crispr, and Other Stocks Cathie Wood Thinks Could Emerge Strong From a Recession -- Barrons.com

Dow Jones
·
10 Apr

Cathie Wood Thinks These Firms Could Emerge Strong From a Recession

Dow Jones
·
10 Apr

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Zacks
·
09 Apr

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

Motley Fool
·
07 Apr

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool
·
07 Apr

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Apr

Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says

MT Newswires Live
·
03 Apr